{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:52:11Z","timestamp":1791989531484,"version":"4.4.0"},"reference-count":135,"publisher":"National Institute for Health and Care Research","issue":"64","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["08\/116\/300"],"award-info":[{"award-number":["08\/116\/300"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"Background<\/jats:title>Intensive treatment (IT) of cardiovascular risk factors can halve mortality among people with established type 2 diabetes but the effects of treatment earlier in the disease trajectory are uncertain.<\/jats:p><\/jats:sec>Objective<\/jats:title>To quantify the cost-effectiveness of intensive multifactorial treatment of screen-detected diabetes.<\/jats:p><\/jats:sec>Design<\/jats:title>Pragmatic, multicentre, cluster-randomised, parallel-group trial.<\/jats:p><\/jats:sec>Setting<\/jats:title>Three hundred and forty-three general practices in Denmark, the Netherlands, and Cambridge and Leicester, UK.<\/jats:p><\/jats:sec>Participants<\/jats:title>Individuals aged 40\u201369 years with screen-detected diabetes.<\/jats:p><\/jats:sec>Interventions<\/jats:title>Screening plus routine care (RC) according to national guidelines or IT comprising screening and promotion of target-driven intensive management (medication and promotion of healthy lifestyles) of hyperglycaemia, blood pressure and cholesterol.<\/jats:p><\/jats:sec>Main outcome measures<\/jats:title>The primary end point was a composite of first cardiovascular event (cardiovascular mortality\/morbidity, revascularisation and non-traumatic amputation) during a mean [standard deviation (SD)] follow-up of 5.3 (1.6) years. Secondary end points were (1) all-cause mortality; (2) microvascular outcomes (kidney function, retinopathy and peripheral neuropathy); and (3) patient-reported outcomes (health status, well-being, quality of life, treatment satisfaction). Economic analyses estimated mean costs (UK 2009\/10 prices) and quality-adjusted life-years from an NHS perspective. We extrapolated data to 30 years using the UK Prospective Diabetes Study outcomes model [version 1.3;\u00a9<\/jats:sup>Isis Innovation Ltd 2010; seewww.dtu.ox.ac.uk\/outcomesmodel<\/jats:uri>(accessed 27 January 2016)].<\/jats:p><\/jats:sec>Results<\/jats:title>We included 3055 (RC,n<\/jats:italic>\u2009=\u20091377; IT,n<\/jats:italic>\u2009=\u20091678) of the 3057 recruited patients [mean (SD) age 60.3 (6.9) years] in intention-to-treat analyses. Prescription of glucose-lowering, antihypertensive and lipid-lowering medication increased in both groups, more so in the IT group than in the RC group. There were clinically important improvements in cardiovascular risk factors in both study groups. Modest but statistically significant differences between groups in reduction in glycated haemoglobin (HbA1c<\/jats:sub>) levels, blood pressure and cholesterol favoured the IT group. The incidence of first cardiovascular event [IT 7.2%, 13.5 per 1000 person-years; RC 8.5%, 15.9 per 1000 person-years; hazard ratio 0.83, 95% confidence interval (CI) 0.65 to 1.05] and all-cause mortality (IT 6.2%, 11.6 per 1000 person-years; RC 6.7%, 12.5 per 1000 person-years; hazard ratio 0.91, 95% CI 0.69 to 1.21) did not differ between groups. At 5 years, albuminuria was present in 22.7% and 24.4% of participants in the IT and RC groups, respectively [odds ratio (OR) 0.87, 95% CI 0.72 to 1.07), retinopathy in 10.2% and 12.1%, respectively (OR 0.84, 95% CI 0.64 to 1.10), and neuropathy in 4.9% and 5.9% (OR 0.95, 95% CI 0.68 to 1.34), respectively. The estimated glomerular filtration rate increased between baseline and follow-up in both groups (IT 4.31 ml\/minute; RC 6.44 ml\/minute). Health status, well-being, diabetes-specific quality of life and treatment satisfaction did not differ between the groups. The intervention cost \u00a3981 per patient and was not cost-effective at costs \u2265\u2009\u00a3631 per patient.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Compared with RC, IT was associated with modest increases in prescribed treatment, reduced levels of risk factors and non-significant reductions in cardiovascular events, microvascular complications and death over 5 years. IT did not adversely affect patient-reported outcomes. IT was not cost-effective but might be if delivered at a reduced cost. The lower than expected event rate, heterogeneity of intervention delivery between centres and improvements in general practice diabetes care limited the achievable differences in treatment between groups. Further follow-up to assess the legacy effects of early IT is warranted.<\/jats:p><\/jats:sec>Trial registration<\/jats:title>ClinicalTrials.gov NCT00237549.<\/jats:p><\/jats:sec>Funding details<\/jats:title>This project was funded by the NIHR Health Technology Assessment programme and will be published in full inHealth Technology Assessment<\/jats:italic>; Vol. 20, No. 64. See the NIHR Journals Library website for further project information.<\/jats:p><\/jats:sec>","DOI":"10.3310\/hta20640","type":"journal-article","created":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T17:33:19Z","timestamp":1472664799000},"page":"1-86","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo\u2013Danish\u2013Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-Europe) study"],"prefix":"10.3310","volume":"20","clinical-trial-number":[{"clinical-trial-number":"nct00237549","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"given":"Rebecca K","family":"Simmons","sequence":"first","affiliation":[{"name":"Medical Research Council Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Knut","family":"Borch-Johnsen","sequence":"additional","affiliation":[{"name":"Holb\u00e6k Hospital, Holb\u00e6k, Denmark"},{"name":"School of Public Health, Department of General Practice, University of Aarhus, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Lauritzen","sequence":"additional","affiliation":[{"name":"School of Public Health, Department of General Practice, University of Aarhus, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy EHM","family":"Rutten","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annelli","family":"Sandb\u00e6k","sequence":"additional","affiliation":[{"name":"School of Public Health, Department of General Practice, University of Aarhus, Aarhus, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"van den Donk","sequence":"additional","affiliation":[{"name":"Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A","family":"Black","sequence":"additional","affiliation":[{"name":"Medical Research Council Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libo","family":"Tao","sequence":"additional","affiliation":[{"name":"Medical Research Council Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward CF","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Public Health and Primary Care, Cambridge Centre for Health Services Research, University of Cambridge, School of Clinical Medicine, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J","family":"Davies","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, Leicester Diabetes Centre, University of Leicester, Leicester General Hospital, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[{"name":"Diabetes Research Centre, Leicester Diabetes Centre, University of Leicester, Leicester General Hospital, Leicester, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J","family":"Sharp","sequence":"additional","affiliation":[{"name":"Medical Research Council Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J","family":"Wareham","sequence":"additional","affiliation":[{"name":"Medical Research Council Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J","family":"Griffin","sequence":"additional","affiliation":[{"name":"Medical Research Council Epidemiology Unit, School of Clinical Medicine, University of Cambridge, Cambridge, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2016,8]]},"reference":[{"key":"key20160826131324773_ref1-bib1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2013","edition":"6th edn"},{"key":"key20160826131324773_ref1-bib2","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/j.1464-5491.2012.03698.x","article-title":"Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs","volume":"29","author":"Hex","year":"2012","journal-title":"Diabet Med"},{"key":"key20160826131324773_ref1-bib3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/bmj.38632.611123.AE","article-title":"Improvements in quality of clinical care in English general practice 1998\u20132003: longitudinal observational study","volume":"331","author":"Campbell","year":"2005","journal-title":"BMJ"},{"key":"key20160826131324773_ref1-bib4","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1136\/bmj.39063.689375.55","article-title":"Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis","volume":"334","author":"Gillies","year":"2007","journal-title":"BMJ"},{"key":"key20160826131324773_ref1-bib5","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(06)69701-8","article-title":"Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study","volume":"368","author":"Lindstr\u00f6m","year":"2006","journal-title":"Lancet"},{"key":"key20160826131324773_ref1-bib6","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/S0140-6736(08)60766-7","article-title":"The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study","volume":"371","author":"Li","year":"2008","journal-title":"Lancet"},{"key":"key20160826131324773_ref1-bib7","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study","volume":"374","author":"Knowler","year":"2009","journal-title":"Lancet"},{"key":"key20160826131324773_ref1-bib8","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s00125-010-1948-9","article-title":"Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing Diabetes Prevention Outcome Study","volume":"54","author":"Gong","year":"2011","journal-title":"Diabetologia"},{"key":"key20160826131324773_ref1-bib9","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S2213-8587(14)70057-9","article-title":"Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing Diabetes Prevention Study: a 23-year follow-up study","volume":"2","author":"Li","year":"2014","journal-title":"Lancet Diabet Endocrinol"},{"key":"key20160826131324773_ref1-bib10","volume-title":"Criteria for Appraisals the Viability, Effectiveness and Appropriateness of a Screening Programme","author":"National Screening Committee","year":"2010"},{"key":"key20160826131324773_ref1-bib11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2337\/diacare.15.7.815","article-title":"Onset of NIDDM occurs at least 4\u20137 yr before clinical diagnosis","volume":"15","author":"Harris","year":"1992","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1002\/(SICI)1096-9136(199604)13:4<337::AID-DIA71>3.0.CO;2-A 2","article-title":"The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults","volume":"13","author":"Thompson","year":"1996","journal-title":"Diabet Med"},{"key":"key20160826131324773_ref1-bib13","doi-asserted-by":"publisher","first-page":"163","DOI":"10.2337\/diacare.20.2.163","article-title":"Diabetes, asymptomatic hyperglycemia, and 22-year mortality in black and white men. The Chicago Heart Association Detection Project in Industry Study","volume":"20","author":"Lowe","year":"1997","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib14","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00125-011-2441-9","article-title":"How much does screening bring forward the diagnosis of type 2 diabetes and reduce complications? Twelve year follow-up of the Ely cohort","volume":"55","author":"Rahman","year":"2012","journal-title":"Diabetologia"},{"key":"key20160826131324773_ref1-bib15","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1136\/bmj.316.7143.1505","article-title":"Shifting of care for diabetes from secondary to primary care, 1990\u20135: review of general practices","volume":"316","author":"Goyder","year":"1998","journal-title":"BMJ"},{"key":"key20160826131324773_ref1-bib16","doi-asserted-by":"publisher","first-page":"673","DOI":"10.2215\/CJN.07891109","article-title":"Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes","volume":"5","author":"Plantinga","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"key20160826131324773_ref1-bib17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/1475-2840-10-39","article-title":"Seven-year mortality in heart failure patients with undiagnosed diabetes: an observational study","volume":"10","author":"Flores-Le Roux","year":"2011","journal-title":"Cardiovasc Diabetol"},{"key":"key20160826131324773_ref1-bib18","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.2337\/diacare.26.9.2604","article-title":"Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn screening study","volume":"26","author":"Spijkerman","year":"2003","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1463-1326.2010.01244.x","article-title":"Screening for type 2 diabetes: an update of the evidence","volume":"12","author":"Simmons","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"key20160826131324773_ref1-bib20","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ije\/28.2.233","article-title":"A Markov chain model to assess the efficacy of screening for non-insulin dependent diabetes mellitus (NIDDM)","volume":"28","author":"Kuo","year":"1999","journal-title":"Int J Epidemiol"},{"key":"key20160826131324773_ref1-bib21","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1006\/pmed.2000.0728","article-title":"Evaluation of a population-based screening for type 2 diabetes: a community-based screening project in Puli, Taiwan","volume":"31","author":"Chang","year":"2000","journal-title":"Prev Med"},{"key":"key20160826131324773_ref1-bib22","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0140-6736(09)62162-0","article-title":"Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis","volume":"375","author":"Kahn","year":"2010","journal-title":"Lancet"},{"key":"key20160826131324773_ref1-bib23","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1016\/S0140-6736(12)61422-6","article-title":"Screening for type 2 diabetes and population mortality over 10 years (ADDITION-Cambridge): a cluster-randomised controlled trial","volume":"380","author":"Simmons","year":"2012","journal-title":"Lancet"},{"key":"key20160826131324773_ref1-bib24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Lancet"},{"key":"key20160826131324773_ref1-bib25","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/0168-8227(95)01064-K","article-title":"Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study","volume":"28","author":"Ohkubo","year":"1995","journal-title":"Diabetes Res Clin Pract"},{"key":"key20160826131324773_ref1-bib26","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group","volume":"317","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"BMJ"},{"key":"key20160826131324773_ref1-bib27","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"key20160826131324773_ref1-bib28","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"key20160826131324773_ref1-bib29","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"key20160826131324773_ref1-bib30","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"key20160826131324773_ref1-bib31","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s001250051594","article-title":"UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis","volume":"44","author":"Stratton","year":"2001","journal-title":"Diabetologia"},{"key":"key20160826131324773_ref1-bib32","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","article-title":"Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64)","volume":"63","author":"Adler","year":"2003","journal-title":"Kidney Int"},{"key":"key20160826131324773_ref1-bib33","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0706245","article-title":"Effect of a multifactorial intervention on mortality in type 2 diabetes","volume":"358","author":"Gaede","year":"2008","journal-title":"N Engl J Med"},{"key":"key20160826131324773_ref1-bib34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.7326\/0003-4819-154-8-201104190-00007","article-title":"Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials","volume":"154","author":"Ismail-Beigi","year":"2011","journal-title":"Ann Int Med"},{"key":"key20160826131324773_ref1-bib35","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(09)60697-8","article-title":"Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials","volume":"373","author":"Ray","year":"2009","journal-title":"Lancet"},{"key":"key20160826131324773_ref1-bib36","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/j.1464-5491.2005.01644.x","article-title":"Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study","volume":"22","author":"Peyrot","year":"2005","journal-title":"Diabetic Med"},{"key":"key20160826131324773_ref1-bib37","doi-asserted-by":"publisher","first-page":"f167","DOI":"10.1136\/bmj.f167","article-title":"Patient reported outcome measures could help transform healthcare","volume":"346","author":"Black","year":"2013","journal-title":"BMJ"},{"key":"key20160826131324773_ref1-bib38","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S0140-6736(08)60672-8","article-title":"Quality and the NHS next stage review","volume":"371","author":"Darzi","year":"2008","journal-title":"Lancet"},{"key":"key20160826131324773_ref1-bib39","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.2337\/diacare.22.7.1125","article-title":"Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). U.K. Prospective Diabetes Study Group","volume":"22","author":"UK Prospective Diabetes Study Group","year":"1999","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib40","doi-asserted-by":"publisher","first-page":"807","DOI":"10.2337\/dc10-1926","article-title":"Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial","volume":"34","author":"Anderson","year":"2011","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib41","volume-title":"Putting Prevention First. Vascular Checks: Risk Assessment and Management","author":"Department of Health","year":"2008"},{"key":"key20160826131324773_ref1-bib42","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/j.1464-5491.2011.03365.x","article-title":"Screening for type 2 diabetes. Lessons from the ADDITION-Europe study","volume":"28","author":"van den Donk","year":"2011","journal-title":"Diabetic Med"},{"key":"key20160826131324773_ref1-bib43","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1111\/j.1464-5491.2010.03056.x","article-title":"Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study","volume":"27","author":"Sargeant","year":"2010","journal-title":"Diabet Med"},{"key":"key20160826131324773_ref1-bib44","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.pcd.2010.06.003","article-title":"Comparison of different stepwise screening strategies for type 2 diabetes: finding from Danish general practice, Addition-DK","volume":"4","author":"Dalsgaard","year":"2010","journal-title":"Primary Care Diabetes"},{"key":"key20160826131324773_ref1-bib45","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1464-5491.2009.02715.x","article-title":"Socioeconomic factors related to attendance at a type 2 diabetes screening programme","volume":"26","author":"Dalsgaard","year":"2009","journal-title":"Diabet Med"},{"key":"key20160826131324773_ref1-bib46","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1093\/fampra\/cmm052","article-title":"Low yield of population-based screening for type 2 diabetes in the Netherlands: the ADDITION Netherlands study","volume":"24","author":"Janssen","year":"2007","journal-title":"Fam Pract"},{"key":"key20160826131324773_ref1-bib47","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/sj.ijo.0801420","article-title":"The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with type 2 diabetes detected by screening","volume":"24","author":"Lauritzen","year":"2000","journal-title":"Int J Obes Relat Metab Disord"},{"key":"key20160826131324773_ref1-bib48","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-11-16","article-title":"Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening","volume":"11","author":"Webb","year":"2010","journal-title":"Trials"},{"key":"key20160826131324773_ref1-bib49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3399\/bjgp09X394851","article-title":"Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study","volume":"59","author":"Janssen","year":"2009","journal-title":"Br J Gen Pract"},{"key":"key20160826131324773_ref1-bib50","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00125-008-1013-0","article-title":"Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study","volume":"51","author":"Sandb\u00e6k","year":"2008","journal-title":"Diabetologia"},{"key":"key20160826131324773_ref1-bib51","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1002\/1520-7560(200005\/06)16:3<164::AID-DMRR103>3.0.CO;2-R","article-title":"Diabetes risk score: towards earlier detection of type 2 diabetes in general practice","volume":"16","author":"Griffin","year":"2000","journal-title":"Diabetes Metab Res"},{"key":"key20160826131324773_ref1-bib52","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2337\/diacare.27.3.727","article-title":"A Danish diabetes risk score for targeted screening: the Inter99 study","volume":"27","author":"Glumer","year":"2004","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib53","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1136\/bmj.39474.922025.BE","article-title":"Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial","volume":"336","author":"Davies","year":"2008","journal-title":"BMJ"},{"key":"key20160826131324773_ref1-bib54","doi-asserted-by":"publisher","first-page":"491","DOI":"10.2337\/diacare.20.4.491","article-title":"Performance of an NIDDM screening questionnaire based on symptoms and risk factors","volume":"20","author":"Ruige","year":"1997","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib55","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(11)60698-3","article-title":"Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial","volume":"378","author":"Griffin","year":"2011","journal-title":"Lancet"},{"key":"key20160826131324773_ref1-bib56","volume-title":"Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation","author":"World Health Organization","year":"1999"},{"key":"key20160826131324773_ref1-bib57","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/1471-2458-9-136","article-title":"The ADDITION-Cambridge trial protocol: a cluster \u2013 randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients","volume":"9","author":"Echouffo-Tcheugui","year":"2009","journal-title":"BMC Public Health"},{"key":"key20160826131324773_ref1-bib58","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators","volume":"355","author":"Heart Outcomes Prevention Evaluation (HOPE) Study Investigators","year":"2000","journal-title":"Lancet"},{"key":"key20160826131324773_ref1-bib59","doi-asserted-by":"publisher","first-page":"614","DOI":"10.2337\/diacare.20.4.614","article-title":"Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)","volume":"20","author":"Pyorala","year":"1997","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib60","volume-title":"Type 2 Diabetes in General Practice \u2013 Diagnosis and Treatment","author":"Royal College of General Practitioners in Denmark","year":"1999"},{"key":"key20160826131324773_ref1-bib61","volume-title":"Clinical Guidelines and Evidence Review for Type 2 Diabetes: Management of Blood Glucose","author":"McIntosh","year":"2001"},{"key":"key20160826131324773_ref1-bib62","first-page":"67","article-title":"Dutch College of General Practitioners. Practice guideline diabetes mellitus type 2","volume":"42","author":"Rutten","year":"1999","journal-title":"Huisarts Wetensch"},{"key":"key20160826131324773_ref1-bib63","volume-title":"Type 2 Diabetes: The Management of Type 2 Diabetes","author":"National Institute for Health and Care Excellence (NICE)","year":"2009"},{"key":"key20160826131324773_ref1-bib64","doi-asserted-by":"publisher","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"key20160826131324773_ref1-bib65","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/S0161-6420(13)38014-2","article-title":"Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12","volume":"98","author":"Early Treatment Diabetic Retinopathy Study Research Group","year":"1991","journal-title":"Ophthalmology"},{"key":"key20160826131324773_ref1-bib66","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.2337\/diacare.17.11.1281","article-title":"A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy","volume":"17","author":"Feldman","year":"1994","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib67","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1185\/030079907X210516","article-title":"Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France","volume":"23","author":"Wu","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"key20160826131324773_ref1-bib68","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","article-title":"Modeling valuations for EuroQol health states","volume":"35","author":"Dolan","year":"1997","journal-title":"Med Care"},{"key":"key20160826131324773_ref1-bib69","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"key20160826131324773_ref1-bib70","volume-title":"SF-36 Health Survey. Manual and Interpretation Guide","author":"Ware","year":"1993"},{"key":"key20160826131324773_ref1-bib71","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.2337\/diacare.22.12.2004","article-title":"The 12-item well-being questionnaire. An evaluation of its validity and reliability in Dutch people with diabetes","volume":"22","author":"Pouwer","year":"1999","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib72","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1017\/S0033291700001719","article-title":"The well-being questionnaire: evidence for a three-factor structure with 12 items (W-BQ12)","volume":"30","author":"Pouwer","year":"2000","journal-title":"Psychol Med"},{"key":"key20160826131324773_ref1-bib73","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1023\/A:1026485130100","article-title":"The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL","volume":"8","author":"Bradley","year":"1999","journal-title":"Qual Life Res"},{"key":"key20160826131324773_ref1-bib74","volume-title":"Handbook of Psychology and Diabetes: a Guide to Psychological Measurements in Diabetes Research and Practice","author":"Bradley","year":"1994"},{"key":"key20160826131324773_ref1-bib75","first-page":"103","article-title":"Updated UKPDS risk engine that estimates primary and secondary cardiovascular disease risk in people with recently-diagnosed or established type 2 diabetes","volume":"61","author":"Coleman","year":"2012","journal-title":"Diabetes"},{"key":"key20160826131324773_ref1-bib76","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/sim.1981","article-title":"Adjusting for partially missing baseline measurements in randomized trials","volume":"24","author":"White","year":"2005","journal-title":"Stat Med"},{"key":"key20160826131324773_ref1-bib77","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"key20160826131324773_ref1-bib78","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.jclinepi.2006.01.014","article-title":"Review: a gentle introduction to imputation of missing values","volume":"59","author":"Donders","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"key20160826131324773_ref1-bib79","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1186\/1471-2458-8-350","article-title":"Screening for type 2 diabetes is feasible, acceptable, but associated with increased short-term anxiety: a randomised controlled trial in British general practice","volume":"8","author":"Park","year":"2008","journal-title":"BMC Public Health"},{"key":"key20160826131324773_ref1-bib80","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/bmj.39308.392176.BE","article-title":"Patients\u2019 experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION (Cambridge) randomised controlled trial","volume":"335","author":"Eborall","year":"2007","journal-title":"BMJ"},{"key":"key20160826131324773_ref1-bib81","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1093\/fampra\/cmq022","article-title":"More than measurement: practice team experiences of screening for type 2 diabetes","volume":"27","author":"Graffy","year":"2010","journal-title":"Fam Pract"},{"key":"key20160826131324773_ref1-bib82","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/dme.12410","article-title":"Does early intensive multifactorial therapy reduce modelled cardiovascular risk in individuals with screen-detected diabetes? Results from the ADDITION-Europe cluster randomized trial","volume":"31","author":"Black","year":"2014","journal-title":"Diabet Med"},{"key":"key20160826131324773_ref1-bib83","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.2337\/dc13-1544","article-title":"Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomised controlled trial: the ADDITION-Europe study","volume":"37","author":"Sandb\u00e6k","year":"2014","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib84","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1007\/s00125-013-3011-0","article-title":"Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Europe): a cluster-randomised trial","volume":"56","author":"van den Donk","year":"2013","journal-title":"Diabetologia"},{"key":"key20160826131324773_ref1-bib85","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s00125-004-1527-z","article-title":"A model to estimate the lifetime health outcomes of patients with type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS) Outcomes Model (UKPDS no. 68)","volume":"47","author":"Clarke","year":"2004","journal-title":"Diabetologia"},{"key":"key20160826131324773_ref1-bib86","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/BF00400195","article-title":"UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance","volume":"34","author":"UK Prospective Diabetes Study Group","year":"1991","journal-title":"Diabetologia"},{"key":"key20160826131324773_ref1-bib87","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1111\/j.1464-5491.2005.01494.x","article-title":"Prognostic value of the Framingham cardiovascular risk equation and the UKPDS risk engine for coronary heart disease in newly diagnosed type 2 diabetes: results from a United Kingdom study","volume":"22","author":"Guzder","year":"2005","journal-title":"Diabet Med"},{"key":"key20160826131324773_ref1-bib88","doi-asserted-by":"publisher","first-page":"708","DOI":"10.2337\/dc08-1918","article-title":"Performance of the UK Prospective Diabetes Study risk engine and the Framingham risk equations in estimating cardiovascular disease in the EPIC-Norfolk cohort","volume":"32","author":"Simmons","year":"2009","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib89","doi-asserted-by":"publisher","first-page":"A37","DOI":"10.1016\/S1098-3015(10)64421-X","article-title":"External validation of the UKPDS outcomes model equations (UKPDS 68) and the UKPDS risk engine equations (UKPDS 56 and 60) in forecasting cardiovascular outcomes in people with type 2 diabetes","volume":"9","author":"McEwan","year":"2006","journal-title":"Value Health"},{"key":"key20160826131324773_ref1-bib90","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/sim.4780100410","article-title":"Multiple imputation in health-care databases: an overview and some applications","volume":"10","author":"Rubin","year":"1991","journal-title":"Stat Med"},{"key":"key20160826131324773_ref1-bib91","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1093\/aje\/kwp425","article-title":"Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation","volume":"171","author":"Lee","year":"2010","journal-title":"Am J Epidemiol"},{"key":"key20160826131324773_ref1-bib92","volume-title":"Multiple Imputation for Nonresponse in Surveys","author":"Rubin","year":"2004"},{"key":"key20160826131324773_ref1-bib93","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s00125-010-1960-0","article-title":"External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes","volume":"54","author":"van Dieren","year":"2011","journal-title":"Diabetologia"},{"key":"key20160826131324773_ref1-bib94","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1002\/sim.4323","article-title":"Bayesian information criterion for longitudinal and clustered data","volume":"30","author":"Jones","year":"2011","journal-title":"Stat Med"},{"key":"key20160826131324773_ref1-bib95","volume-title":"Developing a Protocol for Observational Comparative Effectiveness Research: A User\u2019s Guide","author":"Velentgas","year":"2013"},{"key":"key20160826131324773_ref1-bib96","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jval.2013.06.001","article-title":"Performance of the UKPDS outcomes model for prediction of myocardial infarction and stroke in the ADDITION-Europe trial cohort","volume":"16","author":"Tao","year":"2013","journal-title":"Value Health"},{"key":"key20160826131324773_ref1-bib97","volume-title":"PSSRU Inflation Indices, Secondary PSSRU Inflation Indices","author":"Curtis","year":"2004"},{"key":"key20160826131324773_ref1-bib98","volume-title":"Unit Costs of Health and Social Care 2010","author":"Curtis","year":"2010"},{"key":"key20160826131324773_ref1-bib99","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/dme.12711","article-title":"Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial","volume":"32","author":"Tao","year":"2015","journal-title":"Diabet Med"},{"key":"key20160826131324773_ref1-bib100","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1046\/j.1464-5491.2003.00972.x","article-title":"The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS study no. 65)","volume":"20","author":"Clarke","year":"2003","journal-title":"Diabet Med"},{"key":"key20160826131324773_ref1-bib101","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1463-1326.2008.00886.x","article-title":"Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy","volume":"10","author":"Schwarz","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"key20160826131324773_ref1-bib102","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1177\/027298902400448902","article-title":"Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62)","volume":"22","author":"Clarke","year":"2002","journal-title":"Med Decis Making"},{"key":"key20160826131324773_ref1-bib103","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1464-5491.2007.02188.x","article-title":"PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK","volume":"24","author":"Valentine","year":"2007","journal-title":"Diabet Med"},{"key":"key20160826131324773_ref1-bib104","doi-asserted-by":"crossref","DOI":"10.1007\/1-4020-5511-0","volume-title":"EQ-5D Value Sets: Inventory, Comparative Review and User Guide","author":"Szende","year":"2007"},{"key":"key20160826131324773_ref1-bib105","volume-title":"Guide to the Methods of Technology Appraisal 2013","author":"National Institute for Health and Care Excellence (NICE)","year":"2013"},{"key":"key20160826131324773_ref1-bib106","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v045.i06","article-title":"Multiple imputation using SAS software","volume":"45","author":"Yuan","year":"2011","journal-title":"J Stat Softw"},{"key":"key20160826131324773_ref1-bib107","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1080\/10543406.2011.607736","article-title":"The bootstrap and Markov chain Monte Carlo","volume":"21","author":"Efron","year":"2011","journal-title":"J Biopharm Stat"},{"key":"key20160826131324773_ref1-bib108","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1192\/bjp.187.2.106","article-title":"A guide to cost-effectiveness acceptability curves","volume":"187","author":"Fenwick","year":"2005","journal-title":"Br J Psychiatry"},{"key":"key20160826131324773_ref1-bib109","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/00137910600695676","article-title":"Technical note: constructing tornado diagrams with spreadsheets","volume":"51","author":"Eschenbach","year":"2006","journal-title":"Eng Econ"},{"key":"key20160826131324773_ref1-bib110","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","article-title":"U.K. prospective diabetes study 16. Overview of 6 years\u2019 therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group","volume":"44","author":"UK Prospective Diabetes Study Group","year":"1995","journal-title":"Diabetes"},{"key":"key20160826131324773_ref1-bib111","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1136\/bmj.323.7319.970","article-title":"Randomised controlled trial of structured personal care of type 2 diabetes mellitus","volume":"323","author":"Olivarius","year":"2001","journal-title":"BMJ"},{"key":"key20160826131324773_ref1-bib112","volume-title":"Type 2 Diabetes in General Practice \u2013 An Evidence Based Guideline","author":"Royal College of General Practitioners in Denmark","year":"2004"},{"key":"key20160826131324773_ref1-bib113","first-page":"137","article-title":"Dutch guidelines on type 2 diabetes mellitus. Dutch College of General Practitioners","volume":"49","author":"Rutten","year":"2006","journal-title":"Huisarts Wetensch"},{"key":"key20160826131324773_ref1-bib114","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1056\/NEJMsa055505","article-title":"Pay-for-performance programs in family practices in the United Kingdom","volume":"355","author":"Doran","year":"2006","journal-title":"N Engl J Med"},{"key":"key20160826131324773_ref1-bib115","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0140-6736(11)60442-x","article-title":"Diet or diet plus physical activity versus usual care in patients with newly diagnosed type 2 diabetes: the Early ACTID randomised controlled trial","volume":"378","author":"Andrews","year":"2011","journal-title":"Lancet"},{"key":"key20160826131324773_ref1-bib116","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1046\/j.1365-2362.2002.01090.x","article-title":"Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn Study","volume":"32","author":"Spijkerman","year":"2002","journal-title":"Eur J Clin Invest"},{"key":"key20160826131324773_ref1-bib117","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s00125-008-1156-z","article-title":"The Danish National Diabetes Register: trends in incidence, prevalence and mortality","volume":"51","author":"Carstensen","year":"2008","journal-title":"Diabetologia"},{"key":"key20160826131324773_ref1-bib118","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N Engl J Med"},{"key":"key20160826131324773_ref1-bib119","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"key20160826131324773_ref1-bib120","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Patel","year":"2008","journal-title":"N Engl J Med"},{"key":"key20160826131324773_ref1-bib121","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1111\/j.1464-5491.2012.03644.x","article-title":"Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in type 1 diabetes: results from the Diabetes Control and Complications Trial\/Epidemiology of Diabetes Interventions and Complications","volume":"29","author":"Herman","year":"2012","journal-title":"Diabet Med"},{"key":"key20160826131324773_ref1-bib122","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1046\/j.1464-5491.2003.00931.x","article-title":"How should peripheral neuropathy be assessed in people with diabetes in primary care? A population-based comparison of four measures","volume":"20","author":"Rahman","year":"2003","journal-title":"Diabet Med"},{"key":"key20160826131324773_ref1-bib123","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2337\/diacare.25.3.458","article-title":"Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes","volume":"25","author":"Redekop","year":"2002","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib124","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1464-5491.2010.02968.x","article-title":"Diabetes Care Protocol: effects on patient-important outcomes. A cluster randomized, non-inferiority trial in primary care","volume":"27","author":"Cleveringa","year":"2010","journal-title":"Diabet Med"},{"key":"key20160826131324773_ref1-bib125","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.2337\/dc06-1358","article-title":"Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes","volume":"30","author":"Coleman","year":"2007","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib126","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"key20160826131324773_ref1-bib127","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005","edition":"3rd edn."},{"key":"key20160826131324773_ref1-bib128","doi-asserted-by":"publisher","first-page":"c4093","DOI":"10.1136\/bmj.c4093","article-title":"Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis","volume":"341","author":"Gillett","year":"2010","journal-title":"BMJ"},{"key":"key20160826131324773_ref1-bib129","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.2337\/diacare.26.8.2300","article-title":"The direct medical cost of type 2 diabetes","volume":"26","author":"Brandle","year":"2003","journal-title":"Diabetes Care"},{"key":"key20160826131324773_ref1-bib130","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.jval.2014.03.003","article-title":"Review of utility values for economic modeling in type 2 diabetes","volume":"17","author":"Beaudet","year":"2014","journal-title":"Value Health"},{"key":"key20160826131324773_ref1-bib131","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1056\/NEJMoa0806470","article-title":"10-year follow-up of intensive glucose control in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"key20160826131324773_ref1-bib132","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJMoa0806359","article-title":"Long-term follow-up after tight control of blood pressure in type 2 diabetes","volume":"359","author":"Holman","year":"2008","journal-title":"N Engl J Med"},{"key":"key20160826131324773_ref1-bib133","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00125-010-1681-4","article-title":"The Framingham and UK Prospective Diabetes Study (UKPDS) risk equations do not reliably estimate the probability of cardiovascular events in a large ethnically diverse sample of patients with diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron-MR Controlled Evaluation (ADVANCE) Study","volume":"53","author":"Kengne","year":"2010","journal-title":"Diabetologia"},{"key":"key20160826131324773_ref1-bib134","doi-asserted-by":"publisher","first-page":"d6898","DOI":"10.1136\/bmj.d6898","article-title":"Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials","volume":"343","author":"Hemmingsen","year":"2011","journal-title":"BMJ"},{"key":"key20160826131324773_ref1-bib135","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.pcd.2012.04.005","article-title":"All-cause mortality and pharmacological treatment intensity following a high risk screening program for diabetes. A 6.6 year follow-up of the ADDITION study, Denmark","volume":"6","author":"Lauritzen","year":"2012","journal-title":"Prim Care Diabetes"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20640\/hta20640.xml","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2002528","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta20640\/hta20640.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2003445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T04:17:15Z","timestamp":1718770635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta20640\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":135,"journal-issue":{"issue":"64","published-online":{"date-parts":[[2016,8]]}},"alternative-id":["10.3310\/hta20640"],"URL":"https:\/\/doi.org\/10.3310\/hta20640","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"}]}}